In order to reduce the risk of OHSS, a gonadotropin-releasing hormone (GnRH) antagonist protocol is often used as the first choice for controlled ovarian stimulation in patients with PCOS. This evidence concerns the gene GNRH1 and polycystic ovary syndrome.